Eyecare spending is set to swell fast, but it is not just driven by new diagnoses. By 2030, the ophthalmic drugs market is projected to climb from $27.2B in 2022 to $44.7B, while eyecare devices are forecast to rise from $13.0B in 2023 to $21.5B, with vision testing and diagnostic tools playing a bigger role than many expect. At the same time, screening and teleophthalmology performance gains are pushing earlier detection, changing how demand gets translated into procedures, coverage decisions, and device adoption across the care pathway.
Key Takeaways
- The global ophthalmic drugs market was estimated at $27.2B in 2022 and projected to reach $44.7B by 2030 (compound growth driven largely by eye conditions treated with pharmaceuticals).
- The global contact lenses market was estimated at about $10.0B in 2023 and projected to grow to about $16.9B by 2030.
- The global eyecare devices market was estimated at $13.0B in 2023 and projected to reach $21.5B by 2030 (growth from diagnostic and vision-related devices).
- Vision benefit administration costs are reflected in enrollee premium and copay design; the typical U.S. vision plan uses copays for exams and discounts for lenses/frames (plan design impacts patient out-of-pocket).
- $1.8B U.S. cataract surgery reimbursement market supported by Medicare/claims volume scale (used to quantify procedure economics).
- Digital refraction and remote screening pilots have shown feasibility; studies report that non-mydriatic imaging plus remote grading can detect referable diabetic retinopathy with high sensitivity in clinical evaluation settings.
- COVID-era expansion of teleophthalmology increased throughput; peer-reviewed reviews report high diagnostic agreement between telemedicine and in-person for many ophthalmic conditions.
- 3D printed custom ophthalmic lenses were demonstrated in manufacturing research with reduced lead times vs traditional methods (industry trend).
- The age-standardized prevalence of glaucoma in people age 40+ was estimated at 3.5% globally in a systematic analysis (risk pool for eyecare monitoring).
- A 2019 study using non-mydriatic fundus photography plus remote reading achieved sensitivity of 0.90 (90%) and specificity of 0.98 (98%) for diabetic retinopathy referable detection in a validated setting (screening performance).
- A 2022 systematic review found that AI-based screening for diabetic retinopathy had pooled sensitivity of ~0.90 and specificity of ~0.92 across studies (screening performance).
- 19.0 million people worldwide are estimated to be blind, quantifying the scale of the most severe eyecare need
- 1.7 million cataract surgeries performed annually in the United States (2022), reflecting a major procedural base for ophthalmic services
- In a large U.S. claims analysis, cataract surgery rates were highest in the 75–84 age group, with 10,000+ surgeries per 100,000 persons (age-specific utilization gradient), reflecting strong age dependence
- In the United States, vision insurance is commonly offered through employer-sponsored plans, and typical plan designs use copayments for exams and discounts for frames/lenses (operational model affecting out-of-pocket spending)
Ophthalmic markets are steadily expanding, driven by rising eye conditions, with strong device and drug growth through 2030.
Related reading
01 · Category
Market Size10 stats
01
The global ophthalmic drugs market was estimated at $27.2B in 2022 and projected to reach $44.7B by 2030 (compound growth driven largely by eye conditions treated with pharmaceuticals).
02
The global contact lenses market was estimated at about $10.0B in 2023 and projected to grow to about $16.9B by 2030.
03
The global eyecare devices market was estimated at $13.0B in 2023 and projected to reach $21.5B by 2030 (growth from diagnostic and vision-related devices).
04
The global ophthalmology market was estimated at $57.0B in 2023 and projected to reach $84.0B by 2030 (includes devices, pharma, and therapeutics used in ophthalmology).
05
$4.7B global market size for ophthalmic viscosurgical devices (OVDs) was projected for 2023, supporting large procedural spend tied to cataract and other surgeries.
06
$5.3B global market size for vision testing devices was projected for 2023 and expected to grow by 2030 (diagnostic equipment demand for eyecare providers).
07
$1.6B U.S. market size for eyecare-related imaging devices (e.g., fundus cameras/OCT ecosystem) was cited in industry market coverage for 2023.
08
2.9% CAGR expected for the global eyecare market through 2030 (as summarized by market research coverage of growth rates for eyecare products/services).
09
1.9% CAGR reported for the global eyeglass lenses market through 2032 in a market research forecast, reflecting steady expansion in corrective lens demand.
10
2.1% CAGR of the global vision care market forecast for 2024–2029, indicating steady long-term growth in eyecare-related demand
Interpretation
Market Size Interpretation
The market size data suggests steady, multi-segment expansion in eyecare through the decade, with totals rising from $57.0B in 2023 to $84.0B by 2030 for ophthalmology and an additional long-term growth backdrop of around 2.9% CAGR for the overall global eyecare market.
02 · Category
Cost Analysis2 stats
01
Vision benefit administration costs are reflected in enrollee premium and copay design; the typical U.S. vision plan uses copays for exams and discounts for lenses/frames (plan design impacts patient out-of-pocket).
02
$1.8B U.S. cataract surgery reimbursement market supported by Medicare/claims volume scale (used to quantify procedure economics).
Interpretation
Cost Analysis Interpretation
Under the cost analysis lens, the typical U.S. vision plan keeps costs manageable by pushing expenses into enrollee premium and copay design, while a $1.8B cataract surgery reimbursement market shows that procedure economics are strongly tied to Medicare scale and claims volume.
03 · Category
Industry Trends7 stats
01
Digital refraction and remote screening pilots have shown feasibility; studies report that non-mydriatic imaging plus remote grading can detect referable diabetic retinopathy with high sensitivity in clinical evaluation settings.
02
COVID-era expansion of teleophthalmology increased throughput; peer-reviewed reviews report high diagnostic agreement between telemedicine and in-person for many ophthalmic conditions.
03
3D printed custom ophthalmic lenses were demonstrated in manufacturing research with reduced lead times vs traditional methods (industry trend).
04
Blue-light filtering lens adoption increased after consumer-facing claims; however, clinical evidence varies, with professional societies emphasizing limited benefits for specific outcomes (trend: product differentiation).
05
Dry eye disease remains a major eyecare driver; U.S. optometric practices increasingly sell/dispense eyelid hygiene and prescription biologics as part of dry-eye management pathways (trend).
06
Retail vision industry consolidation continues; in the U.S., private equity activity has increased ownership stakes in optical platforms (trend of consolidation reported by trade press).
07
COVID accelerated telemedicine use; in a 2021 survey, 75% of eye care providers reported using telehealth in some capacity (adoption/performance proxy).
Interpretation
Industry Trends Interpretation
Industry trends are shifting fast as teleophthalmology proves its value with 75% of eye care providers using telehealth in 2021 and remote screening pilots showing high sensitivity for referable diabetic retinopathy, signaling a real move toward scalable, technology-driven care alongside ongoing product and practice model differentiation.
04 · Category
Performance Metrics5 stats
01
The age-standardized prevalence of glaucoma in people age 40+ was estimated at 3.5% globally in a systematic analysis (risk pool for eyecare monitoring).
02
A 2019 study using non-mydriatic fundus photography plus remote reading achieved sensitivity of 0.90 (90%) and specificity of 0.98 (98%) for diabetic retinopathy referable detection in a validated setting (screening performance).
03
A 2022 systematic review found that AI-based screening for diabetic retinopathy had pooled sensitivity of ~0.90 and specificity of ~0.92 across studies (screening performance).
04
In a clinical evaluation, OCT RNFL measurements showed high diagnostic performance for glaucoma with reported AUC >0.9 for discriminating glaucomatous eyes from controls (diagnostic performance metric).
05
A study of optometry workflow automation showed average claim processing time reduced by 45% after adoption of electronic claim submissions (operational performance metric).
Interpretation
Performance Metrics Interpretation
Across key performance metrics, glaucoma prevalence stands at 3.5% globally for ages 40+ while diabetic retinopathy screening consistently shows high diagnostic accuracy around 0.90 sensitivity and 0.92 to 0.98 specificity, and operational gains like a 45% faster claims process suggest the eyecare industry is improving both detection performance and efficiency.
More related reading
05 · Category
Market Demand1 stats
01
19.0 million people worldwide are estimated to be blind, quantifying the scale of the most severe eyecare need
Interpretation
Market Demand Interpretation
Market demand for eyecare is exceptionally large because an estimated 19.0 million people worldwide are blind, underscoring a critical and urgent need for services.
06 · Category
Procedures & Utilization2 stats
01
1.7 million cataract surgeries performed annually in the United States (2022), reflecting a major procedural base for ophthalmic services
02
In a large U.S. claims analysis, cataract surgery rates were highest in the 75–84 age group, with 10,000+ surgeries per 100,000 persons (age-specific utilization gradient), reflecting strong age dependence
Interpretation
Procedures & Utilization Interpretation
Under the Procedures & Utilization category, cataract surgery is a dominant ophthalmic procedure with 1.7 million surgeries performed annually in the U.S. in 2022, and utilization peaks in the 75 to 84 age group at over 10,000 surgeries per 100,000 persons, underscoring strong age-driven demand.
07 · Category
Reimbursement & Costs1 stats
01
In the United States, vision insurance is commonly offered through employer-sponsored plans, and typical plan designs use copayments for exams and discounts for frames/lenses (operational model affecting out-of-pocket spending)
Interpretation
Reimbursement & Costs Interpretation
In the United States, vision insurance is often provided via employer-sponsored plans with copays for exams and discounts for frames and lenses, meaning the reimbursement structure directly shapes out-of-pocket costs for patients.
08 · Category
Regulation & Standards1 stats
01
The FDA regulated medical device classification for intraocular lenses (IOLs) includes multiple classes (II and III depend on device type), indicating regulatory risk tiers tied to product reimbursement pathways
Interpretation
Regulation & Standards Interpretation
Because FDA categorizes intraocular lenses into multiple risk tiers, including Class II and Class III depending on the device type, the Regulation & Standards landscape shows how compliance intensity shifts with classification and can directly affect reimbursement pathways.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Leah Kessler. (2026, February 13). Eyecare Industry Statistics. Gitnux. https://gitnux.org/eyecare-industry-statistics
MLA
Leah Kessler. "Eyecare Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/eyecare-industry-statistics.
Chicago
Leah Kessler. 2026. "Eyecare Industry Statistics." Gitnux. https://gitnux.org/eyecare-industry-statistics.
Sources & references
29 datasets cited across this report · attribution is report-level
+13 additional datasets cited (not shown individually)